Description
Zolmitriptan is a synthetic tryptamine derivative that acts as an agonist at 5-HT1B/1D receptors, binding primarily in the ventral palladium, external globus pallidus, substantia nigra, visual cortex, and nucleus accumbens. This compound displays anti-inflammatory, anti-migraine, and neuroprotective activities. Zolmitriptan treats migraines, inhibiting dilation and inflammation of cranial vessels. This compound also alters NMDA receptor-evoked cGMP and NO signaling. In addition to its modulation of neurotransmitter levels, zolmitriptan inhibits action potential discharge of trigeminal neurons, suggesting antinociceptive activity as well.
References
Lindhe O, Almqvist P, Kågedal M, et al. Autoradiographic Mapping of 5-HT(1B/1D) Binding Sites in the Rhesus Monkey Brain Using [carbonyl-C]zolmitriptan. Int J Mol Imaging. 2011;2011:694179. PMID: 22013519.
Kayser V, Latrémolière A, Hamon M, et al. N-methyl-D-aspartate receptor-mediated modulations of the anti-allodynic effects of 5-HT1B/1D receptor stimulation in a rat model of trigeminal neuropathic pain. Eur J Pain. 2011 May;15(5):451-8. PMID: 20965753.
Stepień A, Chalimoniuk M, Strosznajder J. Serotonin 5HT1B/1D receptor agonists abolish NMDA receptor-evoked enhancement of nitric oxide synthase activity and cGMP concentration in brain cortex slices. Cephalalgia. 1999 Dec;19(10):859-65. PMID: 10668104.
Cumberbatch MJ, Hill RG, Hargreaves RJ. The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats. Eur J Pharmacol. 1998 Nov 27;362(1):43-6. PMID: 9865528.
Pascual J. Mechanism of action of zolmitriptan. Neurologia. 1998 Oct;13 Suppl 2:9-15. PMID: 9859690.
